- Previous Close
3.0600 - Open
3.0600 - Bid 3.1000 x --
- Ask 3.1400 x --
- Day's Range
3.0600 - 3.1200 - 52 Week Range
2.7200 - 5.0500 - Volume
50 - Avg. Volume
20 - Market Cap (intraday)
535.451M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date Mar 5, 2025 - Mar 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
www.savarapharma.comRecent News: YB4P.F
View MorePerformance Overview: YB4P.F
Trailing total returns as of 12/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: YB4P.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: YB4P.F
View MoreValuation Measures
Market Cap
534.77M
Enterprise Value
349.98M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.80
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.39%
Return on Equity (ttm)
-47.96%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-82.94M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
219.9M
Total Debt/Equity (mrq)
13.46%
Levered Free Cash Flow (ttm)
-47.87M